Instead of an exclusive deal, Zymeworks shared its platform non-exclusively with multiple pharma giants. This multi-partner strategy validated the technology, generated capital, and built a portfolio of royalty interests before the company developed its own internal pipeline.

VC Bob Nelsen argues that even if large pharma companies appropriate ideas or gain leverage over US biotech, their financial success is ultimately beneficial. Profitable pharma companies must deploy massive cash reserves, much of which flows back into the biotech ecosystem through M&A, funding the next generation.

With no initial funding, CDR Life leveraged its team's expertise to develop and out-license an ophthalmology program. This non-dilutive deal with Boehringer Ingelheim provided the capital and validation needed to fund its primary mission in oncology and later secure a Series A round.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

Over 20 years, Alnylam raised $7.5 billion. Remarkably, this was evenly split between equity financing from capital markets and non-dilutive funding from pharmaceutical partnerships. This balanced strategy was essential for financing a long, capital-intensive R&D journey while managing shareholder dilution.

While its internal pipeline targets oncology, LabGenius partners with companies like Sanofi to apply its ML-driven discovery platform to other therapeutic areas, such as inflammation. This strategy validates the platform's broad applicability while securing non-dilutive funding to advance its own assets towards the clinic.

Facing capital constraints, biotech companies must make a strategic choice. They can either dilute ownership by raising more venture capital or dilute their pipeline by partnering a secondary asset to fund their lead program. This "equity vs. assets" framework forces a clear-eyed decision on capital strategy.

Astute biotech leaders leverage the tension between public financing and strategic pharma partnerships. When public markets are down, pursue pharma deals as a better source of capital. Conversely, use the threat of a public offering to negotiate more favorable terms in pharma deals, treating them as interchangeable capital sources.

Arcus navigated its capital-intensive early years by using strategic collaborations to bring in over $1 billion in largely non-dilutive funding. This approach allowed the company to reach late-stage clinical milestones and generate valuable data, bridging the gap to a point where public market investors could see tangible value.